JY
AVTX icon

Jeff Yass’s Avalo Therapeutics AVTX Stock Holding History

Jeff Yass’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
+27,227
New +$430K ﹤0.01% 9914
2026
Q1 		– Sell
-210,994
Closed -$3.3M – 13146
2025
Q4 		$3.83M Buy
210,994
+163,596
+345% +$2.76M ﹤0.01% 4471
2025
Q3 		$602K Buy
+47,398
New +$408K ﹤0.01% 8541
2023
Q4 		– Sell
-95
Closed -$2.74K – 12319
2023
Q3 		$2.74K Buy
+95
New +$4.24K ﹤0.01% 11825
2023
Q1 		– Sell
-78
Closed -$95K – 12541
2022
Q4 		$95K Buy
+78
New +$102K ﹤0.01% 11000
2022
Q2 		– Sell
-5
Closed -$11K – 12845
2022
Q1 		$11K Sell
5
-4
-44% -$10K ﹤0.01% 12738
2021
Q4 		$45K Buy
9
+2
+29% +$12K ﹤0.01% 12601
2021
Q3 		$46K Sell
7
-37
-84% -$300K ﹤0.01% 12372
2021
Q2 		$412K Buy
44
+16
+57% +$134K ﹤0.01% 10057
2021
Q1 		$246K Buy
28
+19
+211% +$180K ﹤0.01% 11013
2020
Q4 		$68K Buy
9
+3
+50% +$20.8K ﹤0.01% 10660
2020
Q3 		$42K Buy
6
+1
+20% +$7.52K ﹤0.01% 10245
2020
Q2 		$39K Hold
5
– – ﹤0.01% 9809
2020
Q1 		$36K Buy
+5
New +$52.9K ﹤0.01% 9780
2019
Q4 		– Sell
-4
Closed -$35K – 9687
2019
Q3 		$35K Buy
+4
New +$44.6K ﹤0.01% 9862
2019
Q2 		– Sell
-20
Closed -$329K – 10192
2019
Q1 		$329K Buy
+20
New +$299K ﹤0.01% 7057

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jeff Yass's AVTX Position: Q2 2026 in Review

Jeff Yass opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 27,227 shares worth $503K. The stake represents ﹤0.01% of the portfolio and ranks #9914 among its holdings. This is a return to the name: Jeff Yass previously reported a position in AVTX as recently as Q4 2025.

Jeff Yass first reported a position in AVTX in Q1 2019 and has held it in 16 quarters since. The position peaked at $3.83M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Jeff Yass held 27,227 shares of Avalo Therapeutics worth $503K as of Q2 2026.
  • Avalo Therapeutics was a new Jeff Yass position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9914 holding.
  • Jeff Yass first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 16 quarters since.
  • Jeff Yass's Avalo Therapeutics position peaked at $3.83M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.